Mark Genovese, MD
Enriched profileSenior Vice President, Immunology Development, Eli Lilly and Company · Eli Lilly and Company
Mark Genovese is Senior Vice President, Immunology Development, Eli Lilly and Company at Eli Lilly and Company. OpenAlex indexes 440 publications with 33,650 citations (h-index 90); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Rheumatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Mark Genovese, MD, is Senior Vice President, Immunology Development, Eli Lilly and Company. The public record shows 440 publications with 33,650 citations (h-index 90), centered on Psoriasis / Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 2 companies, 1 NIH-funded awards (2005–2008).
- Most recent indexed publication: 2026 · Arthritis & rheumatology (Hoboken, N.J.)
- Top research focus: Psoriasis / Psoriatic Arthritis
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 31 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
Sponsor: SetPoint Medical Corporation
- A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
Sponsor: AbGenomics B.V Taiwan Branch
- Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
Sponsor: UCB BIOSCIENCES, Inc.
Industry payments
Updated 27 Aug 2026
2 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20251 payment
- Eli Lilly and CompanyProgram year20237 payments
- Gilead Sciences, Inc.Program year20221 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Folate Analog Metabolic Inhibitor100%Methotrexate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2005–2008 per NIH RePORTER. The latest:
- CLINICAL TRIAL: RITUXIMAB WITH OR WITHOUT METHOTREX IN PSORIATIC ARTHRITIS AND P
Stanford University
FY2008$2,276M01RR000070 - FONTOLIZUMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS
Stanford University
FY2007$14,044M01RR000070 - TUMOR NECROSIS FACTOR-ALPHA INHIBITION (ADALIMUMAB) IN OSTEOARTHRITIS
Stanford University
FY2007$5,851M01RR000070
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.
Arthritis & rheumatology (Hoboken, N.J.)
Letter2026 - A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Clinical Trial2023 - Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives.
Patient preference and adherence
Review2023
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
- B.A.
University of Notre Dame
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prnewswire.com ↗
- Director
Rheumatology Clinic, Division of Immunology and Rheumatology, Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Secondary affiliations
appointments beyond the home institution- James W. Raitt
M.D. Professor of Medicine, Emeritus (Active), Division of Immunology and Rheumatology, Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- Q&A on IBD/GI pipeline as Lilly SVP
Pharmaceutical Executive
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pharmexec.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.